Komori
Kidswell Bio (4584) · InitiativeFirst stated

Exploring collaboration in iPS cell-based cardiac muscle regenerative medicine through investment in Heartseed

First written in FY2020-Q2. . Latest entry: FY2020-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Creating New Businesses through Investments in Testing and Diagnostic Device Companies and Regenerative Medicine CompaniesA theme 7 companies write about · 0 as a headwind · 10 as a tailwind

2 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q2First statedAnnual report

    「In addition, in August 2019, the Company invested in Heartseed Co., Ltd., which aims to establish cardiac regenerative medicine using iPS cells, and explored the possibility of collaborating with the company.」

    The Company invested in Heartseed, which aims to establish cardiac regenerative medicine using iPS cells, and is exploring opportunities for collaboration.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Exploring collaboration in iPS cell-based cardiac muscle regenerative medicine through investment in Heartseed | Kidswell Bio Corporation (4584) | Komori